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A non-interventional study evaluating the effectiveness of rotigotine 
and levodopa combination therapy in younger versus older patients 
with Parkinson’s disease 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note: 
These data were previously presented at the 21st International Congress of Parkinson’s 
Disease and Movement Disorders, June 4–8 2017; Vancouver, Canada. 
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ABSTRACT 
Background: PD0013 was a 6-month non-interventional study in clinical-practice 
comparing effectiveness and tolerability of rotigotine+levodopa in younger (<70years) 
vs. older (≥70years) Parkinson’s disease (PD) patients. 
Methods: Patients previously received levodopa for ≥6-months as monotherapy or in 
combination with another dopamine-agonist (DA). Primary variable: Unified PD Rating 
Scale (UPDRS) Part-II change from baseline to end-of-observation-period (EOP). 
Results: 91 younger/99 older patients started rotigotine; 68 younger/62 older patients 
completed the study. Most switched from levodopa+another DA. Addition of rotigotine 
as first DA was more common in older patients (20.2% vs.15.4%). Mean±SD rotigotine-
exposure: 6.1±3.4mg/24h younger vs. 4.9±2.4mg/24h older. Eleven patients changed 
levodopa dose during the study.  
At EOP, improvement in mean UPDRS-II was greater in younger patients (p=0.0289). 
UPDRS-II responder-rate (≥20% decrease in UPDRS-II score) was higher in younger 
patients (42.3% vs. 25.9%). Improvement across age-groups was similar on PD Sleep 
Scale-2 and Clinical Global Impressions-Improvement Scale. Adverse-drug-reactions 
(ADRs), and discontinuations because of ADRs, were more common among older 
patients. There were no new safety-signals. 
Conclusions: Despite low rotigotine doses, when added to levodopa or switched from 
levodopa+another DA, rotigotine led to greater improvement in UPDRS-II in younger 
patients (<70years). Assessment of individual patient data revealed clinically-meaningful 
improvements in UPDRS-II in both age-groups. 
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Trial registration: NCT02227355 
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1. Introduction 
The optimal treatment strategy for Parkinson’s disease (PD) has been a topic of debate 
for many years. While levodopa is considered the most effective treatment for patients 
with PD [1], long-term use of levodopa is associated with the development of motor 
complications [2-4]. Dopamine agonists (DAs) have been used as monotherapy in 
patients with early PD, often with the aim to delay treatment with levodopa and possibly 
delay the development of motor complications, or as adjunctive therapy to levodopa in 
patients with advanced PD [5].   
Levodopa is sometimes used as first-line therapy in suitable patients [1,6]. As the 
risk of developing dyskinesias or motor fluctuations is closely linked to cumulative 
levodopa dose, physicians may choose to initiate treatment with low doses of levodopa 
[1,6,7]. Non-motor symptoms, such as sleep disturbances [8], are a key driver of quality 
of life in patients with PD [9], but tend to be a secondary consideration in decisions on 
initial treatment. When PD symptoms worsen with advancing disease, one treatment 
option for patients on first-line levodopa is to add low doses of DAs, rather than 
increasing levodopa dose, which may reduce the risk of dyskinesias developing and 
provide advantages for symptoms that respond better to DAs [4,6,10]. Administering low 
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doses of levodopa and DAs may further reduce the likelihood of other complications of 
chronic dopamine replacement therapy, such as impulse control disorders or dopamine 
dysregulation syndrome [11,12]. 
Personalized medicine is particularly relevant for the treatment of PD, with important 
considerations including patient age, comorbidities, and lifestyle [13]. PD primarily 
affects older patients (>60 years) [14], and as life expectancy in patients with PD has 
increased, patients are treated for longer, leading to more treatment options . As such, 
many current PD treatment guidelines may not be valid for PD patients with ‘healthy 
ageing’ [13]. Due to increasing patient longevity, the previously mentioned issues linked 
to chronic levodopa exposure are also pertinent [15].  
DAs are underused in the elderly because of a perception of increased side effects, 
despite evidence indicating they may be well tolerated and provide clinical benefit in 
certain older PD patients [15-17]. For example, a retrospective analysis of four 
randomized, placebo-controlled clinical studies with the non-ergoline DA rotigotine, 
comparing younger with older patients with PD has shown rotigotine to be generally well 
tolerated in both populations [18]. However, that analysis had several limitations 
including a small older age cohort and an overall study population that, having met 
predefined eligibility criteria, may have been comparatively healthier than the general 
population of patients with PD. In addition, the included studies were not designed for 
the comparison of different age groups. 
The exclusion of patients from PD research on the basis of an upper age limit is 
frequent and makes clinical trials data less relevant to real-life clinical practice [19].  
Elderly patients often have a greater prevalence of comorbidities and age-related 
medical conditions, making them unable to meet clinical study entry requirements. As 
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such, they are frequently under-represented in clinical studies, making it difficult to 
generalize findings to the numerous older patients seen in clinical practice [19]. Real-
world studies offer an important insight into patient treatment and outcomes in current 
clinical practice in a large heterogeneous population of patients.  
This prospective, non-interventional study was conducted in routine clinical practice 
to evaluate the clinical effects of combined treatment with rotigotine and levodopa, in 
younger (<70 years), and older (≥70 years) patients who had previously received 
levodopa as monotherapy or in combination with another DA. 
2. Patients and method 
2.1. Study design and patients 
This multicenter non-interventional study (PD0013; NCT02227355) was conducted 
between September 2014 and June 2016 at 41 sites in five countries (France, 
Germany, Italy, Spain and the United Kingdom). The study consisted of three visits 
(baseline [Visit 1], end of titration of rotigotine dose [Visit 2], and end of observation 
period [Visit 3]) over approximately 6 months. Patient age groups (<70 years and ≥70 
years) were selected according to the German Society of Neurology guidelines [20]. 
The Unified Parkinson’s Disease Rating Scale (UPDRS) Part II [21] and Parkinson’s 
Disease Sleep Scale-2 (PDSS-2) [22] were completed at the baseline and end-of-
observation visits, and the Clinical Global Impressions-Improvement (CGI-I; global 
rating of change of condition) [23] was completed at the end-of-observation visit. Over 
the entire study period, physicians documented all changes in medication in a 
medication diary. 
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Patients were included if they had signed a patient data consent form (the signature 
was provided by the spouse for a small number of patients with writing difficulties). In 
the United Kingdom, the form had to be signed by patients with the capacity to consent, 
and patients who had been diagnosed with dementia were to be excluded. Patients 
were aged ≥18 years with idiopathic PD (Hoehn & Yahr [HY] stage 1−4), and had not 
received rotigotine within 28 days prior to baseline. They had to have been receiving 
levodopa as monotherapy or in combination with a DA other than rotigotine, have been 
on levodopa therapy for at least 6 months, and to have responded to initial levodopa 
therapy (i.e. no primary non-responders). The decision by the treating physician to 
prescribe rotigotine transdermal patch was based on clinical judgment (e.g. 
undertreatment with levodopa monotherapy, intolerance and/or ineffectiveness of 
another DA) before the patient was enrolled in the study. Patients were treated during 
the study according to current clinical practices for their condition. No additional 
diagnostic or monitoring procedures were applied. No restrictions were placed on 
previous or concomitant medications or on rescue medications. Patients were free to 
withdraw from the study at any time, without prejudice to their continued care. 
The study protocol, amendments, and patient informed consent were reviewed by a 
national, regional, or Independent Ethics Committee or Institutional Review Board. The 
study was conducted in compliance with legal requirements for noninterventional 
studies. 
 
2.2. Variables 
The primary variable was the change from baseline to the end of the observation 
period in the UPDRS II total score.  
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Secondary variables included change from baseline to the end of the observation 
period in levodopa dose and in PDSS-2 total score. UPDRS II responder rate (i.e. 
proportion of patients who achieved a ≥20% decrease in UPDRS II total score), CGI-I 
score and CGI-I response rate (i.e. proportion of patients who were very much or much 
improved) at the end of the observation period were also assessed.  
Safety measurements included the occurrence of adverse drug reactions (ADRs) 
reported by the patient or observed by the treating physician, and treatment 
discontinuations because of ADRs. 
 
2.3. Statistical analyses and study size 
Safety assessments were performed on the safety set (SS), which consisted of all 
enrolled patients who received at least one dose of rotigotine. Analysis of the 
effectiveness variables was conducted on the full analysis set (FAS), which consisted of 
all patients in the SS who had a baseline and post-baseline UPDRS II total score. 
Based on the PREFER study [24], the mean (SD) change in UPDRS Part II total 
score was assumed to be –3 (6.0). A precision of the estimate of 1.0 was considered 
sufficient for this study. With a sample size of 138 evaluable patients for the FAS, a two-
sided 95% confidence interval (CI) for the difference in means would extend 1.0 from 
the observed mean, assuming the SD was known to be 6.0 (with the CI based on the 
large sample z statistic). Assuming a 20% dropout rate, 170 patients had to be included 
in the study to obtain 69 evaluable patients per group in the FAS.  
The primary variable was assessed with an analysis of covariance (ANCOVA) that 
included age as a fixed effect, UPDRS II total score at baseline, and type of site (office 
or hospital), as covariates to calculate least-square (LS) means and 95% CIs (between 
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group difference analyzed with a two-sided two-sample t test). UPDRS II and CGI-I 
response rates between age groups were analyzed with Fisher’s exact test. PDSS-2 
was analyzed similarly to the primary variable. If a patient did not complete the 
observation period (i.e. early withdrawal) or did not have an end of observation visit 
UPDRS Part II total or CGI-I score, the patient was considered a non-responder.  
Subgroup analyses were performed on the primary effectiveness variable by 
gender, previous therapy (rotigotine add-on for levodopa monotherapy; rotigotine switch 
for levodopa with DA combination therapy), duration of PD at baseline (≤5 years; >5 
years), and severity of PD by HY stage at baseline (group 1, HY stage 1–2; group 2, HY 
stage 3–4).  
All p-values are exploratory, and not corrected for multiple testing. The analyses 
were performed using SAS Version 9.4.  
3. Results 
3.1. Baseline demographics, disease characteristics and patient disposition 
A total of 195 patients were enrolled and 190 were included in the SS; 91 were <70 
years of age and 99 were ≥70 years of age (Table 1). A greater proportion of patients in 
the older group had advanced disease, though mean time since PD diagnosis was 
similar (Table 1). One hundred and thirty patients completed the study and 60 
discontinued (23 were <70 years of age and 37 were ≥70 years of age; Table 1). The 
primary reasons for discontinuation were the occurrence of ADR to rotigotine, lack of 
efficacy, withdrawal of consent (not because of an ADR) and other reasons.  
 
3.2. Rotigotine and levodopa doses 
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 The overall mean (SD) duration of rotigotine treatment during the observation period 
was 150.2 (76.6) days. The mean (SD) duration of rotigotine treatment during the 
observation period was greater in the <70 years group (157.4 [68.1] days) than in the 
≥70 years group (143.6 [83.4] days), with mean (SD) daily exposures of 6.1 (3.4) 
mg/day and 4.9 (2.4) mg/day, respectively. During the titration period, the mean (SD) 
duration of rotigotine treatment was 61.2 (39.0) days in the <70 years group and 52.4 
(37.0) days in the ≥70 years group. During maintenance, the mean (SD) duration of 
rotigotine treatment was 107.0 (55.3) days in the <70 years group and 118.6 (58.3) days 
in the ≥70 years group. 
The overall mean (SD) daily dose of rotigotine during the observation period was 5.5 
(3.0) mg/day (6.1 [3.4] mg/day in the <70 years group and 4.9 [2.4] mg/day in the ≥70 
years group). The mean (SD) daily dose of rotigotine during the titration period was 5.6 
(3.4) mg/day in the <70 years group and 4.4 (2.3) mg/day in the ≥70 years group. 
During maintenance, the mean (SD) daily dose of rotigotine was 6.3 (3.6) mg/day in the 
<70 years group and 5.4 (2.2) mg/day in the ≥70 years group. 
The mean (SD) daily dose of levodopa (mg/day) at baseline was 637.6 (523.2) in the 
younger group and 584.7 (417.9) in the older group. Most patients had no change in 
levodopa dose from baseline to the end of the observation period: five patients in the 
younger group had a dose change (one decrease of 100 mg/day and four increases 
ranging from 100 to 350 mg/day) and six patients in the older group had a dose change 
(two decreases of 125 and 400 mg/day and four increases ranging from 50 to 250 
mg/day), and the mean change from baseline to the end of observation period was 
minimal (9.1 [51.3] and 0.0 [57.7] mg/day, respectively).  
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3.3. Concomitant therapies 
Overall, 110 out of 190 patients (57.9%) used concomitant medications to treat PD. The 
most commonly used were rasagiline (40 [44.0%] younger vs. 23 [23.2%] older), 
pramipexole dihydrochloride (10 [11.0%] younger vs. five [5.1%] older), 
amantadine/amantadine derivatives (10 [11.0%] younger vs. six [6.1%] older) and 
ropinirole hydrochloride (eight [8.8%] younger vs. three [3.0%] older). All other 
concomitant medications were used by ≤5% of patients overall. 
 
3.4. Effectiveness 
3.4.1. Primary variable 
There were decreases in mean UPDRS II total score from baseline to the end of the 
observation period in both age groups, with a greater decrease in the younger group 
(Figure 1).  
Subgroup analyses of the primary variable revealed decreases from baseline in 
UPDRS II total score for the younger group, among patients with longer PD duration 
(i.e. >5 years), more advanced disease (i.e. HY stage 3–4) and in patients who had 
received levodopa in combination with a DA as their previous therapy, while the older 
group showed a slight increase, no change, or smaller decrease, respectively (Table 2). 
There were decreases from baseline in both age groups among patients with disease 
duration ≤5 years and those with less advanced disease (i.e. HY stage 1–2), and little 
change in patients who had received levodopa monotherapy as their previous therapy, 
with no clear difference between age groups (Table 2). 
 
 
Page 11 of 40    April 2018 
 
3.4.2. Secondary variables 
In line with the primary variable, the overall UPDRS II responder rate was 34.0%, and 
was higher in patients aged <70 years than in those aged ≥70 years (Figure 2). The 
mean improvement in PDSS-2 was similar in both age groups (Figure 3). The overall 
responder rate (very much, much improved) on the CGI-I was 27.0% and was similar 
across age groups (Figure 4).  
 
3.4.3. Post-hoc analyses 
Post-hoc analyses of CGI-I data revealed that around 45% of patients in each age 
group who switched to rotigotine because of insufficient efficacy with their previous DA 
were improved (minimally/much/very much improved) at the end of the observation 
period (Suppl Table 1). Additionally, more improvement than worsening after rotigotine 
treatment was seen on the CGI-I in both age groups across the reasons (motor and 
non-motor symptoms) for rotigotine specifically being prescribed (Suppl Table 2). 
Another post-hoc analysis evaluated the change in UPDRS II total score according to 
individual patients’ HY stage, disease duration and rotigotine dose. The resulting bubble 
plot (Suppl Figure 1) provides a visualization of the disease characteristics of each 
patient and their response to rotigotine. While there appeared to be some fast 
progressors (i.e. patients at HY stage 3 or 4 with relatively short disease duration), and 
some slow progressors (i.e. patients at HY stage 1 or 2 with relatively long disease 
duration), these were the exceptions and response to rotigotine did not appear to 
correlate with a particular subgroup based on length of disease or HY stage. Moreover, 
it was apparent that many patients with large improvements in UPDRS II total score 
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received a low dose of rotigotine, whereas some patients had only a minimal response 
despite receiving a higher dose of rotigotine. 
 
3.5. Safety 
Overall, 49 out of 190 patients (25.8%) had an ADR, with 104 events in total (Table 3). 
Patients in the ≥70 years group reported more ADRs than those in the <70 years group 
(67 events in 31 of 99 patients [31.3%] in the ≥70 years group and 37 events in 18 of 91 
patients [19.8%] in the <70 years group). A total of 36 of 190 patients (18.9%) reported 
ADRs which led to the withdrawal of rotigotine, with a higher proportion in the older age 
group. One patient in the older group reported two serious ADRs, confusional state and 
hallucinations on a mean dose during the observation period of rotigotine 3.3 mg/day 
and levodopa at 150 mg/day; both events were considered to be related to rotigotine 
and led to the patient withdrawing from the study. No deaths were reported during the 
study. One patient died 1 day after the study ended. The death was caused by a 
myocardial infarction, which was not related to study treatment. No pregnancies or 
mean changes in body mass index were reported. Overall, the safety data did not raise 
any new safety signals. 
4. Discussion 
This was a multicenter, non-interventional study conducted in routine clinical practice 
comparing outcomes in patients with PD who were <70 years of age versus ≥70 years 
of age treated with levodopa and the rotigotine transdermal patch as combination 
therapy. The study evaluated the effectiveness and tolerability of rotigotine in 195 
enrolled patients across 41 sites in France, Germany, Italy, Spain and the United 
Page 13 of 40    April 2018 
Kingdom. The recommended dosing for rotigotine is between 2 and 8 mg/day in early 
stages of PD, or between 4 and 16 mg/day in advanced stages of PD with motor 
fluctuations. In the current study, the mean daily dose prescribed was 5.5 mg (6.1 
mg/day for younger patients and 4.9 mg/day for older patients), suggesting patients 
were generally treated with low rotigotine doses. 
Analysis of the primary variable revealed decreases from baseline to the end of the 
observation period in UPDRS II total score (Activities of Daily Living) in both age 
groups, with a greater decrease in the younger age group. This may have been due to 
younger patients tolerating higher doses of rotigotine. Although this is a general finding 
with DAs, a strict dose related response in young versus old has not been 
confirmed,[25] and individual patient data did not suggest a clear relationship between 
rotigotine dose and response (as discussed below). The smaller improvement observed 
in the older group might be expected given that age-related changes as well as PD-
related changes in motor behavior may affect the ability to perform activities of daily 
living. Indeed, age at PD-onset may be an independent factor for more rapid disease 
progression, partly attributable to the influence of comorbid diseases [26-28], and 
therefore UPDRS II scores in older patients may not be improved by only treating PD 
symptoms with dopaminergic therapy. Nevertheless, individual patient data for the 
change in total UPDRS II score suggested there were clinically meaningful 
improvements in 41–54% of patients in the younger age group and 35–44% of patients 
in the older age group, based on a cut-off of 2 or 3 points’ improvement on UPDRS II. 
According to Schrag et al, an improvement on UPDRS II total score of 2 represents a 
minimally clinically important change (MCIC) in patients at HY stage 1/1.5 and 2 and an 
improvement of 3 represents a MCIC in patients at HY stage 2.5/3 [29]. This was based 
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on a sample of patients aged ~63 years and thus may underestimate the proportion of 
patients with a clinically meaningful improvement in the older age group in our study. 
There were greater decreases in UPDRS II total score for younger versus older 
patients who had >5 years’ PD duration, who were at HY stage 3 or 4 at baseline or 
who were receiving levodopa with DA combination therapy at baseline, while both age 
groups showed similar changes in UPDRS II total score among patients with ≤5 years’ 
PD duration or who were at HY stage 1 or 2. Again, some of the mean changes from 
baseline (–2 for HY stage 1–2; –3 or lower for HY stage 3–4) observed for the subgroup 
analyses could potentially be regarded as clinically meaningful improvements [29]. 
These findings suggested there may be subtypes of patients who respond better to 
rotigotine treatment. However, in a subsequent post-hoc analysis of individual patient 
data, response to rotigotine did not appear to correlate with HY stage or disease 
duration in this patient population. Moreover, the bubble plot indicated that patients who 
responded to rotigotine tended to be treated with relatively low rotigotine doses. One 
could speculate that there exists a subgroup of patients that responds well to treatment 
with rotigotine, even on low doses, and perhaps, another subgroup of patients that does 
not respond well, even if the dose is high. It must be noted that this was an 
observational study and as such, rotigotine dose was not assigned in a randomized 
manner. It would be interesting to further explore what factors mediate the response to 
rotigotine.  
In general, the results for the secondary variables supported those of the primary 
variable. The overall UPDRS II responder rate for patients was 34.0%, with a higher 
proportion of patients responding to treatment in the younger group than in the older 
group (42.3% vs. 25.9%). The overall CGI-I responder rate (‘much improved’ and ‘very 
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much improved’) was 27.0%, with a similar proportion of patients categorized as CGI-I 
responders in the ≥70 years versus <70 years age group (24.4% vs. 29.6%). Post-hoc 
analyses of CGI-I data indicated that almost half of patients in each age group who 
changed DA because of insufficient efficacy with their previous DA, felt improved 
(minimally/much/very much improved) on this measure when switched to rotigotine. 
Small patient numbers across other categories limits interpretation of the remaining 
data. Similarly, across the various motor and non-motor reasons for rotigotine 
prescription, in both age groups, there was generally more improvement than worsening 
after rotigotine treatment. Overall, there was some improvement in the mean PDSS-2 
score in both age groups, with patients in the younger group having a slightly larger 
improvement; this is consistent with the results of the CGI-I post-hoc analysis showing 
perceived improvements in sleep disturbances after treatment with rotigotine, and with 
previous research [8]. The CGI-I also revealed a tendency for patients in both age 
groups to perceive more improvement than worsening in motor symptoms following the 
addition of rotigotine to their treatment regimen.  
Eleven patients had a change in levodopa dose (mg/day) during the study, with little 
change in mean dose from baseline to the end of observation period in either age 
group, indicating this was not the cause of the effectiveness findings. 
The post-hoc analyses revealed other interesting insights into the treatment of PD 
patients with rotigotine in routine clinical practice. For example, no patient who had HY 
stage 4 disease was treated with the highest approved dose of rotigotine (16 mg/day), 
whereas some patients with HY stage 2 disease were treated with this dose, which is 
not aligned with the product posology recommendation. Many patients at HY stage 3 or 
4, or with long disease duration, or showing no improvement on UPDRS II, were treated 
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with rotigotine 2 mg/day and it is unknown why they were not treated with a higher 
rotigotine dose. 
Forty-nine patients (25.8%) reported a total of 104 ADRs; the most common ADRs 
experienced by ≥5% of patients were related to administration site conditions, nervous 
system disorders and gastrointestinal disorders. Patients in the older group generally 
reported more ADRs, and there were slightly more withdrawals because of ADRs than 
in the younger group, which may suggest slightly higher tolerability in younger patients, 
although there could be other reasons. Two serious ADRs – confusional state and 
hallucinations – were reported for one patient in the older group. These events were 
considered to be related to rotigotine and led to the patient withdrawing from the study. 
There were no reports of fatal ADRs during the study.  
Limitations of this study include the short duration of the observation period (~6 
months). Moreover, when UPDRS II was measured, it was not stipulated whether the 
patient should be in the ON or OFF state, which could have added variability to the 
data. Furthermore, it may have been relevant to include UPDRS III as an outcome 
measure since improvement in UPDRS III sub-items may influence improvement in 
UPDRS II. Finally, this was an exploratory study, which does not allow for formal 
statistical testing of hypotheses, or the inclusion of a placebo group (though evidence 
for age group differences in placebo response in PD is lacking [30,31]), and so the 
results must be interpreted with caution. Future high-quality studies could be helpful to 
further assess the effectiveness of rotigotine in particular sub-populations of patients 
with PD. 
Page 17 of 40    April 2018 
5. Conclusions 
In this large real-world study, rotigotine in combination with levodopa provided greater 
improvement to activities of daily living in patients aged <70 years than ≥70 years. 
Improvements between age groups were similar for the secondary effectiveness 
variables, PDSS-2 and CGI-I. Rotigotine when added to levodopa therapy was well-
tolerated overall although more patients in the older group reported, or withdrew 
because of, ADRs. Most ADRs were consistent with stimulation of dopamine receptors, 
use of transdermal patch and the clinical course of the patient’s underlying disease.  
 
Acknowledgements 
The authors thank the patients and their caregivers in addition to the investigators and 
their teams who contributed to this study. The authors acknowledge Nicole Meinel, PhD, 
CMPP (Evidence Scientific Solutions, London, UK) for writing assistance, funded by 
UCB Pharma (Brussels, Belgium), Elisabeth Dohin, MD (UCB Pharma, Brussels, 
Belgium) and Karin Annoni, MD (UCB Pharma, Milan, Italy) for scientific and medical 
input into the data analyses and interpretation, and Suzannah Ryan, PhD, EU 
Publication Manager (UCB Pharma, Dublin, Ireland) for publication coordination. The 
authors thank Javier Alcazar Perez, MD (former employee of UCB Pharma, Madrid, 
Spain) for his contributions to the running of the study and analysis of the data. 
 
Funding 
This study was funded by UCB Pharma, Brussels, Belgium, and is registered with 
ClinicalTrials.gov (NCT02227355). 
Page 18 of 40    April 2018 
 
Financial and competing interest disclosure 
Dirk Woitalla has received personal compensation from UCB Pharma, GlaxoSmithKline, 
Orion Pharma, Zambone, Bial, Bayer and AbbVie for consulting services. Antoine 
Dunac, Ali Safavi, Juan Carlos Gomez Esteban and Nicola Pavese report no conflicts of 
interest. Maria-Gabriella Ceravolo has received personal compensation from UCB 
Pharma for consulting services. K. Ray Chaudhuri has received research support from 
UCB Pharma, AbbVie and Britannia Pharma 2006–2011; consultancy fees/honoraria 
from UCB Pharma, AbbVie, US WorldMeds, Otsuka, Mundipharma and Britannia; 
provides a consultant/advisory role for AbbVie (2010–present), Britannia (2009–
present), Mundipharma (2012–present), UCB Pharma (2010–present); receives funding 
for speaker activities for AbbVie, Britannia, Mundipharma, UCB Pharma, Zambon and 
Medtronic; receives educational grants from AbbVie, Britannia, Medtronic and UCB 
Pharma; grants/honoraria from the NIHR, Parkinson’s UK, EU, AbbVie, Britannia, 
Medtronic and UCB Pharma; holds a patent for a product referred to in the CME/CPD 
program that is marketed by a commercial organization; and is currently participating in, 
designing, or running a clinical trial (within the past 2 years) for Toledo, Neupark, 
PANDA and the Newron PDGF study. Lars Joeres and Jan-Christof Schuller are 
salaried employees of UCB Pharma and receive stock options from their employment. 
Mahnaz Asgharnejad is a former employee of UCB Pharma (Raleigh, NC) who received 
stock options from her employment. 
Page 19 of 40    April 2018 
References 
1. Zhang J, Tan LC. Revisitng the medical management of Parkinson’s disease: 
levodopa versus dopamine agonist. Curr Neuropharmacol. 2016;14(4):356–363. 
2. Hauser RA, McDermott MP, Messing S. Factors associated with the development 
of motor fluctuations and dyskinesias in Parkinson disease. Arch Neurol. 
20016;63(12):1756–1760. 
3. Scott NW, Macleod AD, Counsell CE. Motor complications in an incident 
Parkinson’s disease cohort. Eur J Neurol. 2016;23(2):304–312. 
4. Stocchi F, Vacca L, Radicati FG. How to optimize the treatment of early stage 
Parkinson’s disease. Transl Neurodegener. 2015;4:4. 
5. Antonini A, Tolosa E, Mizuno Y, et al. A reassessment of risks and benefits of 
dopamine agonists in Parkinson’s disease. Lancet Neurol. 2009;8(10):929–937. 
6. Oertel WH, Berardelli A, Bloem BR, Bonuccelli U, et al. Chapter 14, Early 
(uncomplicated) Parkinson’s disease. In: Gilhus NE, Barnes MR, Brainin M, 
editors. European handbook of neurological management. Volume 1. Blackwell 
Publishing Ltd; 2011. p. 217–236. * Provides scientifically supported treatment 
recommendations for early stage Parkinson’s disease. 
7.  Stocchi F, Rascol O, Kieburtz K, et al. Initiating levodopa/carbidopa therapy with 
and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann 
Neurol. 2010;68(1):18–27. 
8.  Trenkwalder C, Kies B, Rudwinska M, et al. Rotigotine effects on early morning 
function and sleep in Parkinson’s disease: a double-blind, randomized, placebo-
controlled study (RECOVER). Mov Disord. 2011;26(1):90–99. 
Page 20 of 40    April 2018 
9. Chaudhuri KR, Healy DG, Schapira AH. Non-motor symptoms of Parkinson’s 
disease: diagnosis and management. Lancet Neurol. 2006;5(3):235–245. 
10. Talati R, Baker WL, Patel AA, et al. Adding a dopamine agonist to preexisting 
levodopa therapy vs. levodopa therapy alone in advanced Parkinson’s disease: a 
meta analysis. Int J Clin Prac. 2009;63(4):613–623.* Meta-analysis showing that 
adding a DA to pre-existing levodopa therapy is more beneficial in reducing PD 
symptoms compared with levodopa alone in patients not controlled on 
monotherapy, particularly those patients with wearing-off phenonenon from 
levodopa therapy. 
11. Giovannoni G, O’Sullivan JD, Turner K, et al. Hedonistic homeostatic 
dysregulation in patients with Parkinson’s disease on dopamine replacement 
therapies. J Neurol Neurosurg Psychiatry. 2000;68(4):423–428. 
12. Weiss HD, Marsh L. Impulse control disorders and compulsive behaviors 
associated with dopaminergic therapies in Parkinson disease. Neurol Clin Pract. 
2012;2(4):267–274. 
13. Titova N, Jenner P, Chaudhuri KR. The future of Parkinson’s treatment – 
personalised and precision medicine. Eur Neurol Rev. 2017;12(1):15–16.* 
Provides a rationale for a personalised medicine approach in Parkinson’s 
disease.  
14. de Lau LM, Breteler MM. Epidemiology of Parkinson’s disease. Lancet Neurol. 
2006;5(6):525–535. 
15. Silver D. Impact of functional age on the use of dopamine agonists in patients 
with Parkinson disease. Neurologist. 2006;12(4):214–223. 
Page 21 of 40    April 2018 
16. Appiah-Kubi LS, Nisbet A, Burn DJ, et al. Use and tolerability of cabergoline in 
young and older people with Parkinson’s disease: a multi-center observational 
study. J Appl Res. 2003;3(4):356–362. 
17. Shulman LM, Minagar A, Rabinstein A, et al. The use of dopamine agonists in 
very elderly patients with Parkinson’s disease. Mov Disord. 2000;15(4):664–668. 
18. Oertel W, LeWitt P, Giladi N, et al. Treatment of patients with early and advanced 
Parkinson’s disease with rotigotine transdermal system: age-relationship to 
safety and tolerability. Parkinsonism Relat Dis. 2013;19(1):37–42.* Post-hoc 
analysis comparing the safety and tolerability profile of rotigotine in patients with 
early or advanced Parkinson’s disease aged <75 years vs. ≥75 years; rotigotine 
was generally well tolerated in both age groups. The authors provide a caveat 
that it was a relatively healthy study population with relatively few patients in the 
older age group so may not be representative of the general PD population. 
19. Fitzsimmons PR, Blayney S, Mina-Corkill S, et al. Older participants are 
frequently excluded from Parkinson’s disease research. Parkinsonism Relat 
Disord. 2012;18(5):585–589.** Systematic analysis of data from 206 actively 
recruiting Parkinson’s disease research studies extracted from World Health 
Organization Clinical Trials Registry Platform, which found that patients were 
often excluded based on an arbitrary upper age limit, particularly in smaller 
studies. 
20. Eggert K, Oertel W, Reichmann H, et al. Leitlinien: Parkinson-Syndrome – 
Diagnostik und Therapie. German Society of Neurology Guidelines; Scientific 
and Medicinal Association 030/010. 2012. 
Page 22 of 40    April 2018 
21. Martinez-Martin P, Gil-Nagel A, Gracia LM, et al. Unified Parkinson’s Disease 
Rating Scale characteristics and structure. The Cooperative Multicentric Group. 
Mov Disord. 1994;9(1):76–83. 
22. Trenkwalder C, Kohnen R, Högl B, et al. Parkinson’s disease sleep scale--
validation of the revised version PDSS-2. Mov Disord. 2011;26(4):644–652. 
23. Guy W, editor. ECDEU Assessment Manual for Psychopharmacology. Rockville, 
MD: US Department of Heath, Education, and Welfare Public Health Service 
Alcohol, Drug Abuse, and Mental Health Administration; 1976. 
24. LeWitt PA, Lyons KE, Pahwa R, et al. Advanced Parkinson disease treated with 
rotigotine transdermal system: PREFER Study. Neurology. 2007;68(16):1262–
1267. 
25. Appiah-Kubi L, Nisbet A, Burn DJ, et al. Use and tolerability of cabergoline in 
young and older people with Parkinson’s disease: a multicentre observational 
study. J Applied Research 2003;3(4):356–362. 
26. Wickremaratchi MM, Ben-Shlomo Y, Morris HR. The effect of onset age on the 
clinical features of Parkinson’s disease. Eur J Neurol. 2009;16(4):450–456.** A 
systematic review assessing the relationship between clinical features and age at 
onset of Parkinson’s disease finding evidence suggesting that patients with 
younger Parkinson’s disease onset have slower disease progression. 
27. Diederich NJ, Moore CG, Leurgans SE, et al. Parkinson disease with old-age 
onset: a comparative study with subjects with middle-age onset. Arch Neurol. 
2003;60(4):529–533. 
28. Lenka A, Padmakumar C, Pal PK. Treatment of older Parkinson's disease. Int 
Rev Neurobiol. 2017;132:381–405. 
Page 23 of 40    April 2018 
29. Schrag A, Sampaio C, Counsell N, et al. Minimal clinically important change on 
the unified Parkinson’s disease rating scale. Mov Dis. 2006;21(8):1200–1207.** 
This study provided estimates for cutoffs defining clinically important changes in 
UPDRS II and III scores. 
30.   Bingel U, Colloca L, Vase L. Mechanisms and clinical implications of the placebo 
effect: is there a potential for the elderly? A mini-review. Gerontology. 
2011;57(4):354–363. 
31. Weimer K, Colloca L, Enck P. Age and sex as moderators of the placebo 
response – an evaluation of systematic reviews and meta-analyses across 
medicine. Gerontology. 2015;61(2):97–108. 
Page 24 of 40    April 2018 
Tables and Figures 
Table 1. Baseline demographics, disease characteristics and patient disposition. 
 <70 years ≥70 years 
 
All patients 
Enrolled, n 94 101 195 
SS, n (%) 91 (96.8) 99 (98.0) 190 (97.4) 
FAS, n (%) 78 (83.0) 81 (80.2) 159 (81.5) 
Male, n (%) 57 (73.1) 47 (58.0) 104 (65.4) 
Age, years    
Mean ± SD 61.0 (6.7) 76.2 (4.0) 68.7 (9.4) 
Weight, kg    
Mean ± SD 77.86 (16.36) 73.74 (13.36) 75.79 (15.02) 
BMI, kg/m2    
Mean ± SD 27.07 (4.87) 26.11 (4.04) 26.59 (4.48) 
Time since diagnosis of PD, years    
Mean ± SD 5.7 (4.6) 5.8 (5.6) 5.8 (5.1) 
Median (min, max) 5.0 (0, 23) 4.0 (0, 30) 5.0 (0, 30) 
Duration of PD, n (%)    
≤5 years 41 (52.6) 48 (59.3) 89 (56.0) 
>5 years 37 (47.4) 33 (40.7) 70 (44.0) 
Prior therapy, n (%)a    
Levodopa monotherapy 12 (15.4) 17 (21.0) 29 (18.2) 
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Levodopa with DA 63 (80.8) 64 (79.0) 127 (79.9) 
Levodopa dose, n (%)a    
<400 mg/day 29 (37.2) 29 (35.8) 58 (36.5) 
≥400 mg/day 46 (59.0) 52 (64.2) 98 (61.6) 
HY subgroups, n (%)    
HY 1−2 57 (73.1) 41 (50.6) 98 (61.6) 
HY 3−4 21 (26.9) 40 (49.4) 61 (38.4) 
Stage of PD, n (%)    
Early 49 (62.8) 35 (43.2) 84 (52.8) 
Advanced with motor fluctuations 23 (29.5) 30 (37.0) 53 (33.3) 
Advanced without motor fluctuations 6 (7.7) 16 (19.8) 22 (13.8) 
Reason for change in PD treatment, n (%)    
Intolerance to current PD treatment 5 (6.4) 11 (13.6) 16 (10.1) 
Insufficient efficacy 56 (71.8) 63 (77.8) 119 (74.8) 
Treatment compliance 7 (9.0) 4 (4.9) 11 (6.9) 
Other 10 (12.8) 3 (3.7) 13 (8.2) 
Motor symptoms, n (%)    
Dyskinesia 15 (19.2) 19 (23.5) 34 (21.4) 
Dystonia 13 (16.7) 8 (9.9) 21 (13.2) 
Motor fluctuations 29 (37.2) 29 (35.8) 58 (36.5) 
Bradykinesia 40 (51.3) 45 (55.6) 85 (53.5) 
Tremor 25 (32.1) 34 (42.0) 59 (37.1) 
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Other 10 (12.8) 15 (18.5) 25 (15.7) 
Non-motor symptoms, n (%)    
Gastrointestinal tract symptoms 12 (15.4) 17 (21.0) 29 (18.2) 
Urinary tract symptoms 11 (14.1) 16 (19.8) 27 (17.0) 
Sexual dysfunction 6 (7.7) 2 (2.5) 8 (5.0) 
Cardiovascular-related symptoms 3 (3.8) 2 (2.5) 5 (3.1) 
Symptoms associated with attention and 
memory dysfunction or apathy 5 (6.4) 9 (11.1) 14 (8.8) 
Emergence of hallucinations or delusions 1 (1.3) 3 (3.7) 4 (2.5) 
Presence of depression, anxiety or anhedonia 10 (12.8) 13 (16.0) 23 (14.5) 
Sleep disturbances or fatigue 28 (35.9) 30 (37.0) 58 (36.5) 
Pain (unrelated to other causes) 15 (19.2) 13 (16.0) 28 (17.6) 
Miscellaneous (e.g. diplopia, weight loss) 3 (3.8) 5 (6.2) 8 (5.0) 
Completed the study, n (%) 68 (74.7) 62 (62.6) 130 (68.4) 
Discontinued study, n (%) 23 (25.3) 37 (37.4) 60 (31.6) 
ADR 11 (12.1) 16 (16.2) 27 (14.2) 
Lack of efficacy 5 (5.5) 7 (7.1) 12 (6.3) 
Lost to follow-up 0 3 (3.0) 3 (1.6) 
Disease remission 0 0 0 
Consent withdrawn 0 4 (4.0) 4 (2.1) 
Other 7 (7.7) 7 (7.1) 14 (7.4) 
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aValues do not add up to 100% because of missing data. 
ADR: adverse drug reaction; BMI: body mass index; DA: dopamine agonist; FAS: full analysis set; HY: 
Hoehn & Yahr; PD: Parkinson’s disease; SD: standard deviation; SS: safety set. 
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Table 2. Mean change in UPDRS II total score by subgroup (FAS). 
Variable 
<70 years 
N = 78 
≥70 years 
N = 81 
LS mean (95% CI) difference  
≥70 years vs. <70 yearsa 
Male, n 57 47  
Baseline, mean ± SD 12.6 ± 5.7 14.0 ± 6.5  
Change from baseline, LS mean ± SE –2.6 ± 0.6 
p < 0.0001 
–0.9 ± 0.7 
p = 0.2039 
1.7 (–0.2, 3.6) 
p = 0.0737 
Female, n 21 34  
Baseline, mean ± SD 11.6 ± 7.8 13.8 ± 8.2  
Change from baseline, LS mean ± SE –2.6 ± 1.0 
p = 0.0153 
–0.9 ± 0.8 
p = 0.2645 
1.7 (–0.8, 4.2) 
p = 0.1804 
Duration of PD    
≤5 years, n 41 48  
Baseline, mean ± SD 10.8 ± 5.6 12.1 ± 6.3  
Change from baseline, LS mean ± SE –2.5 ± 0.6 
p < 0.0001 
–2.1 ± 0.5 
p = 0.0001 
0.4 (–1.1, 1.9) 
p = 0.5677 
>5 years, n 37 33  
Baseline, mean ± SD 14.0 ± 6.6 16.6 ± 7.7  
Change from baseline, LS mean ± SE –2.6 ± 1.0 
p = 0.0100 
1.2 ± 1.0 
p = 0.2311 
3.8 (1.1, 6.5) 
p = 0.0007 
Prior therapy    
Levodopa monotherapy, n 12  17  
Baseline, mean ± SD 14.8 ± 7.2 15.2 ± 6.5  
Change from baseline, LS mean ± SE –1.9 ± 1.4 
p = 0.1923 
–0.8 ± 1.2 
p = 0.4941 
1.1 (–2.8, 4.9) 
p = 0.5722 
Levodopa with DA, n 63 64  
Baseline, mean ± SD 11.9 ± 6.0 13.6 ± 7.4  
Change from baseline, LS mean ± SE  –2.8 ± 0.6 
p < 0.0001 
–0.9 ± 0.6  
p = 0.1284 
1.9 (0.2, 3.5) 
p = 0.0284 
HY subgroups    
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HY 1−2, n 57  41  
Baseline, mean ± SD 10.7 ± 5.3 10.5 ± 5.3  
Change from baseline, LS mean ± SE –2.1 ± 0.5  
p < 0.0001 
–2.2 ± 0.6 
p = 0.0003 
–0.1 (–1.5, 1.4) 
p = 0.9149 
HY 3−4, n 21 40  
Baseline, mean ± SD 16.7 ± 6.8 17.5 ± 7.2  
Change from baseline, LS mean ± SE –3.8 ± 1.3  
p = 0.0056 
0.1 ± 0.9  
p = 0.9398 
3.9 (0.6, 7.1) 
p = 0.0199 
aLS mean, SE, difference and 95% CI are from an analysis of covariance (ANCOVA) model with age group as a 
fixed effect and UPDRS part score at baseline and type of site (office/hospital) as covariates. 
CI: confidence interval; DA: dopamine agonist; FAS: full analysis set; HY: Hoehn & Yahr; LS: least squares; PD: 
Parkinson’s disease; SD: standard deviation; SE: standard error; UPDRS: Unified Parkinson’s Disease Rating 
Scale. 
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Table 3. Adverse drug reactions (SS). 
MedDRA (Version 19.0) 
 
<70 years 
N = 91 
n (%) [#] 
≥70 years 
N = 99 
n (%) [#] 
All patients 
N = 190 
n (%) [#] 
Any ADRa 18 (19.8) [37] 31 (31.3) [67] 49 (25.8) [104] 
Serious ADRsb 0 1 (1.0) [2] 1 (0.5) [2] 
ADRs leading to withdrawal of rotigotine 14 (15.4) [33] 22 (22.2) [52] 36 (18.9) [85] 
Fatal ADRs 0 0 0 
ADRs occurring in ≥5% patients in either age groupc    
Application and instillation site reactionsd  4 (4.4) [5] 7 (7.1) [8] 11 (5.8) [13] 
Nausea 2 (2.2) [2] 9 (9.1) [9] 11 (5.8) [11] 
Drug ineffectivee 2 (2.2) [2] 8 (8.1) [8] 10 (5.3) [10] 
Dizziness 2 (2.2) [2] 6 (6.1) [6] 8 (4.2) [8] 
Data are number (%) of patients reporting ≥1 ADR. [#] is number of individual occurrences of the ADR. 
aAn ADR was defined as an adverse event related to rotigotine. 
bOne older patient reported two serious ADRs, confusional state and hallucinations, considered related to 
rotigotine, leading to withdrawal from the study. 
cPreferred Term, unless otherwise specified. 
dHigh Level Term. 
eIncludes investigated reported terms such as lack of efficacy, lack of beneficial effect. 
ADR: adverse drug reaction; SS: safety set. 
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Suppl Table 1. Post-hoc analysis: reason for DA exchange and outcome of CGI-I (FAS). 
Reason for DA Exchange CGI-I item, n (%) 
<70 years 
N = 78 
≥70 years 
N = 81 
Intolerance to current PD treatment Not assessed / missing 0 0 
 Very much improved 0 0 
 Much improved 0 5 (6.2) 
 Minimally improved 2 (2.6) 1 (1.2) 
 No change 1 (1.3) 5 (6.2) 
 Minimally worse 2 (2.6) 0 
 Much worse 0 0 
 Very much worse 0 0 
Insufficient efficacy Not assessed / missing 0 1 (1.2) 
 Very much improved 1 (1.3) 3 (3.7) 
 Much improved 16 (20.5) 15 (18.5) 
 Minimally improved 19 (24.4) 17 (21.0) 
 No change 13 (16.7) 15 (18.5) 
 Minimally worse 5 (6.4) 10 (12.3) 
 Much worse 2 (2.6) 1 (1.2) 
 Very much worse 0 1 (1.2) 
Treatment compliance Not assessed / missing 0 0 
 Very much improved 0 1 (1.2) 
 Much improved 1 (1.3) 1 (1.2) 
 Minimally improved 4 (5.1) 0 
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 No change 1 (1.3) 0 
 Minimally worse 1 (1.3) 1 
 Much worse 0 0 
 Very much worse 0 1 
Other Not assessed / missing 0 0 
 Very much improved 1 (1.3) 0 
 Much improved 0 0 
 Minimally improved 5 (6.4) 1 (1.2) 
 No change 1 (1.3) 0 
 Minimally worse 2 (2.6) 2 (2.5) 
 Much worse 1 (1.3) 0 
 Very much worse 0 0 
CGI-I: Clinical Global Impressions-Improvement; DA: dopamine agonist; FAS: full analysis set. 
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Suppl Table 2. Post-hoc analysis: reason for rotigotine prescription and outcome of CGI-I (FAS). 
Reason for rotigotine prescriptiona CGI-I item, n (%) 
<70 years 
N = 78 
≥70 years 
N = 81 
Motor symptoms    
Motor fluctuations Not assessed / missing 0 1 (1.2) 
 Very much improved 0 0 
 Much improved 10 (12.8) 5 (6.2) 
 Minimally improved 11 (14.1) 9 (11.1) 
 No change 4 (5.1) 9 (11.1) 
 Minimally worse 2 (2.6) 4 (4.9) 
 Much worse 2 (2.6) 0 
 Very much worse 0 1 (1.2) 
Bradykinesia Not assessed / missing 0 1 (1.2) 
 Very much improved 1 (1.3) 3 (3.7) 
 Much improved 9 (11.5) 8 (9.9) 
 Minimally improved 13 (16.7) 13 (16.0) 
 No change 12 (15.4) 11 (13.6) 
 Minimally worse 4 (5.1) 7 (8.6) 
 Much worse 1 (1.3) 1 (1.2) 
 Very much worse 0 1 (1.2) 
Tremor Not assessed / missing 0 1 (1.2) 
 Very much improved 0 1 (1.2) 
 Much improved 4 (5.1) 8 (9.9) 
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 Minimally improved 11 (14.1) 9 (11.1) 
 No change 9 (11.5) 9 (11.1) 
 Minimally worse 0 6 (7.4) 
 Much worse 1 (1.3) 0 
 Very much worse 0 0 
Non-motor symptoms    
Gastrointestinal tract symptoms Not assessed / missing 0 0 
 Very much improved 1 (1.3) 1 (1.2) 
 Much improved 3 (3.8) 4 (4.9) 
 Minimally improved 5 (6.4) 5 (6.2) 
 No change 1 (1.3) 2 (2.5) 
 Minimally worse 2 (2.6) 3 (3.7) 
 Much worse 0 1 (1.2) 
 Very much worse 0 1 (1.2) 
Sleep disturbances and fatigue Not assessed / missing 0 1 (1.2) 
 Very much improved 1 (1.3) 2 (2.5) 
 Much improved 6 (7.7) 8 (9.9) 
 Minimally improved 14 (17.9) 9 (11.1) 
 No change 6 (7.7) 7 (8.6) 
 Minimally worse 1 (1.3) 1 (1.2) 
 Much worse 0 1 (1.2) 
 Very much worse 0 1 (1.2) 
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aTable only includes motor and non-motor fluctuations with responses for >20 patients in either age group. 
CGI-I: Clinical Global Impressions-Improvement; DA: dopamine agonist; FAS: full analysis set. 
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Figure 1. LS mean change from baseline to end of observation period in UPDRS II total 
score (FAS). 
FAS: full analysis set; UPDRS: Unified Parkinson’s Disease Rating Scale.  
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Figure 2. UPDRS II Responder Rate at End of Observation Period (FAS). 
*Responder rate defined as a decrease in percent change from baseline ≥20%. If a 
patient withdrew early or did not have a Visit 3 assessment, they were counted as a 
non-responder. 
FAS: full analysis set; OP: observation period; UPDRS: Unified Parkinson’s Disease 
Rating Scale. 
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Figure 3. LS mean change from baseline to end of observation period in PDSS-2 total 
score (FAS). 
FAS: full analysis set; PDSS: Parkinson’s Disease Sleep Scale. 
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Figure 4. CGI-I at End of Observation Period (FAS). 
CGI-I: Clinical Global Impressions-Improvement; FAS: full analysis set.  
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Suppl Figure 1. Post-hoc analysis: change in UPDRS II total score as a function of HY 
stage, disease duration and rotigotine dose of individual patients (FAS). 
Note: In order to reduce overlay in the plot, HY stage and duration of disease data were 
‘jittered’ before plotting (i.e. some random noise was added). 
FAS: full analysis set; HY: Hoehn & Yahr; UPDRS: Unified Parkinson’s Disease Rating 
Scale. 
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